SAN DIEGO, Sept. 08, 2022 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a study demonstrating the utility of optical genome mapping (OGM) in the part of a workflow to assess the quality of hypoimmunogenic induced pluripotent stem cells (iPSCs) that could be used in regenerative medicine. This research provides scientific and practical support for the ability of GMOs to detect cryptic and balanced structural variants (SV) in CRISPR-edited cells, some of which have not been detected by karyotyping, and which may impact genomic integrity of iPSCs.
The expansion of iPSC-mediated cell therapy faces risks due to immune rejection caused by human leukocyte antigen (HLA) mismatches between donor and recipient. Researchers in this study developed a novel strategy for the reduction of immune rejection using CRISPR-Cas9 genome editing to selectively knock out HLA-A and HLA-B genes while retaining HLA-C and other non-HLAs. classics.
To optimize the selection of CRISPR-Cas9-edited iPSC subclones, study researchers performed a rigorous assessment of genomic integrity using whole genome sequencing (WGS), karyotyping (KT ) and GMOs. In the study, OGM matched karyotype and genome sequencing results of deletions and translocations and identified complicated genomic rearrangements missed by other methods. GMO was also able to detect distinctive mutations in iPSCs that researchers could then avoid using.
“Bionano is pleased to see research that demonstrates the utility of GMOs in the field of regenerative medicine. This article describes a rigorous assessment of genomic integrity that could be applied to iPSCs that could potentially be used to restore functionally impaired tissues or organs. We are pleased that the authors included GMO as part of the development of new methods to analyze the quality of genome-edited cells. We believe that this strategy could be beneficial not only for the simplification of the production process, but also for the reduction of unintended genomic mutations at off-target sites or unexpected large deletions at target sites that may be caused by the effects of Guide RNA (gRNA),” commented Erik Holmlin, PhD, President and CEO of Bionano Genomics.
The document is available at: https://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501(22)00075-4
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to find answers to complex questions in biology and medicine. The company’s mission is to transform the way the world views the genome through GMO solutions, diagnostic services and software. The company offers GMO solutions for applications in basic, translational and clinical research. Through its Lineagen business, the company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorders and other neurodevelopmental disorders. Through its BioDiscovery business, the company also offers a leading-edge, platform-independent software solution that integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and a report of copy number variants, single nucleotide variants and absence of heterozygosity across the genome in a consolidated view. For more information, visit www.bionanogenomics.com, www.lineagen.com Where www.biodiscovery.com
Bionano Genomics Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “could”, “believe” and similar expressions (as well as other words or expressions referring to future events, conditions or circumstances) convey uncertainty of future events or results and are intended to identify such forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyzes or current expectations regarding, among other things, GMO’s ability and utility to detect cryptic and balanced SVs in edited cells by CRISPR, the utility of GMOs in quality and genomic integrity assessment of iPSCs, and the possibility that GMOs are part of a cell therapy workflow. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied by such forward-looking statements. Factors that could cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; failure of GMO to detect cryptic and balanced SVs in CRISPR-edited cells; the failure of the GMO to be part of the genomic integrity assessment of iPSCs; the failure of results from future studies to support those demonstrated in the presentations referenced in this press release; changes in our strategic and business plans; our ability to obtain sufficient financing to fund our strategic plans and marketing efforts; the ability of medical and research institutions to obtain funding to support the adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition generally, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on form 10-K for the year ended December 31, 2021 and in other filings subsequently filed by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date they are made and are based on management’s assumptions and estimates as of that date. We undertake no obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations:
Amy Conrad
tip of the juniper
+1 (858) 366-3243
amy@juniper-point.com
